Commonly given in a combination called ICE Ifosfamide, Carboplatin, and Etopicide also known as (VP-16). It is commonly given to people as an adjunct drug in lung cancers or mets to lungs. It screws with blood counts (like most chemo) and these require strict monitoring. Particularly low platelets, low white counts and the development of anemia. Also known as Vepesid.

There is a second generation version of this in clinical trials http://www.clinicaltrials.gov/ct/show/NCT00282022?order=2

I think if you look at this it will be interesting for anyone considering clinical trials (not the use of this drug as a combination therapy) because you can see how clinical trials are structured and how they target the population of people that are allowed in a trial in this example. This gives you some idea how difficult it can be to qualify for a clinical trial drug. Again not the specific drug you are asking about in this trial so pay no attention to the info in that link. This is an offspring of that drug.